GPCR

SEC source: 0001415889-24-015683 · form4-06052024_110646.xml · derivative · entry 3

Lin Xichen · CIK 0001962926 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 213,800

Underlying: Ordinary Shares · 106,200 shares

Expires 2029-09-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4 of the shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

F3 · balance_after: This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 106,200 Ordinary Shares.

SEC source: 0001415889-24-015683 · form4-06052024_110646.xml · nonDerivative · entry 2

Lin Xichen · CIK 0001962926 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 85,707

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The Ordinary Shares were converted into American Depositary Shares as reported in Table II above.

SEC source: 0001415889-24-015683 · form4-06052024_110646.xml · nonDerivative · entry 1

Lin Xichen · CIK 0001962926 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 191,907

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-008551 · form4-03182025_080303.xml · derivative · entry 4

Yoon Jun · CIK 0001962414 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,294

Underlying: Ordinary Shares · 2,082 shares

Expires not disclosed

F6 · derivative.exercise_price: Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date.

F7 · kind: Voluntary reporting of the acquisition of 694 ADSs by the Reporting Person on May 20, 2024 pursuant to the Issuer's Employee Share Purchase Plan.

F6 · derivative.exercise_date: Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date.

F6 · derivative.expiration_date: Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date.

F1 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

SEC source: 0001415889-24-008567 · form4-03192024_080323.xml · derivative · entry 2

Bach Mark Allen · CIK 0001962610 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,352

Underlying: Ordinary Shares · 65,352 shares

Expires 2034-03-14

F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

SEC source: 0001415889-24-008567 · form4-03192024_080323.xml · nonDerivative · entry 1

Bach Mark Allen · CIK 0001962610 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,235

F1 · kind: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2024, subject to Reporting Person's continued service on such dates.

SEC source: 0001415889-24-008561 · form4-03192024_080344.xml · derivative · entry 3

Stevens Raymond C · CIK 0001698149 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 335,481

Underlying: Ordinary Shares · 335,481 shares

Expires 2034-03-14

F3 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

SEC source: 0001415889-24-008561 · form4-03192024_080344.xml · nonDerivative · entry 1

Stevens Raymond C · CIK 0001698149 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,198,346

F1 · kind: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2024, subject to Reporting Person's continued service on such dates.

SEC source: 0001415889-24-008572 · form4-03192024_080311.xml · derivative · entry 2

Lin Xichen · CIK 0001962926 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,486

Underlying: Ordinary Shares · 213,486 shares

Expires 2034-03-14

F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

SEC source: 0001415889-24-008572 · form4-03192024_080311.xml · nonDerivative · entry 1

Lin Xichen · CIK 0001962926 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,707

F1 · kind: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2024, subject to Reporting Person's continued service on such dates.

SEC source: 0001415889-24-008569 · form4-03192024_080346.xml · derivative · entry 2

Ma Yingli · CIK 0001963664 · CHIEF TECHNOLOGY OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,494

Underlying: Ordinary Shares · 91,494 shares

Expires 2034-03-14

F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

SEC source: 0001415889-24-008569 · form4-03192024_080346.xml · nonDerivative · entry 1

Ma Yingli · CIK 0001963664 · CHIEF TECHNOLOGY OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,729

F1 · kind: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2024, subject to Reporting Person's continued service on such dates.

SEC source: 0001415889-24-008566 · form4-03192024_080315.xml · derivative · entry 3

Yoon Jun · CIK 0001962414 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,134

Underlying: Ordinary Shares · 148,134 shares

Expires 2034-03-14

F3 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

SEC source: 0001415889-24-008566 · form4-03192024_080315.xml · nonDerivative · entry 1

Yoon Jun · CIK 0001962414 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,123,133

F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2024, subject to Reporting Person's continued service on such dates.

SEC source: 0001415889-24-008783 · form4a-03202024_110306.xml · derivative · entry 1

Bach Mark Allen · CIK 0001962610 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,352

Underlying: Ordinary Shares · 65,352 shares

Expires 2034-03-14

F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price as that of the Ordinary Shares rather than the American Depositary Shares ("ADSs"). The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.

F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

F3 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

SEC source: 0001415889-24-008780 · form4a-03202024_110300.xml · derivative · entry 1

Stevens Raymond C · CIK 0001698149 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 335,481

Underlying: Ordinary Shares · 335,481 shares

Expires 2034-03-14

F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price as that of the Ordinary Shares rather than the American Depositary Shares ("ADSs"). The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.

F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

F3 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

SEC source: 0001415889-24-008784 · form4a-03202024_110328.xml · derivative · entry 1

Lin Xichen · CIK 0001962926 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,486

Underlying: Ordinary Shares · 213,486 shares

Expires 2034-03-14

F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price as that of the Ordinary Shares rather than the American Depositary Shares ("ADSs"). The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.

F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

F3 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

SEC source: 0001415889-24-008781 · form4a-03202024_110339.xml · derivative · entry 1

Yoon Jun · CIK 0001962414 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,134

Underlying: Ordinary Shares · 148,134 shares

Expires 2034-03-14

F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price as that of the Ordinary Shares rather than the American Depositary Shares ("ADSs"). The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.

F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

F3 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

SEC source: 0001415889-24-008782 · form4a-03202024_110344.xml · derivative · entry 1

Ma Yingli · CIK 0001963664 · CHIEF TECHNOLOGY OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,494

Underlying: Ordinary Shares · 91,494 shares

Expires 2034-03-14

F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price as that of the Ordinary Shares rather than the American Depositary Shares ("ADSs"). The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.

F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

F3 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

SEC source: 0000950170-24-032542 · ownership.xml · derivative · entry 3

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned

Disclosed balance after: 1,541,868

Underlying: Ordinary Shares · 65,991 shares

Expires not disclosed

F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

SEC source: 0001209191-24-003392 · doc4.xml · derivative · entry 3

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned

Disclosed balance after: 1,563,865

Underlying: Ordinary Shares · 1,575 shares

Expires not disclosed

F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

SEC source: 0001209191-23-059755 · doc4.xml · derivative · entry 3

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned

Disclosed balance after: 1,564,390

Underlying: Ordinary Shares · 76,230 shares

Expires not disclosed

F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F2 · price: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

SEC source: 0001209191-23-057698 · doc4.xml · derivative · entry 6

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP

Disclosed balance after: 32,169

Underlying: Ordinary Shares · 48,258 shares

Expires not disclosed

F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $62.35 to $62.63. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

SEC source: 0001209191-23-057698 · doc4.xml · derivative · entry 5

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP

Disclosed balance after: 2,733

Underlying: Ordinary Shares · 4,104 shares

Expires not disclosed

F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $62.35 to $62.63. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

SEC source: 0001209191-23-053321 · doc4.xml · derivative · entry 6

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP

Disclosed balance after: 48,255

Underlying: Ordinary Shares · 48,258 shares

Expires not disclosed

F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP ("Fund VI") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP ("FPCPLSA") converted 16,407 ordinary shares to 5,469 ADSs. Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS as shown in Column 9.

F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $65.52 to $65.70. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP ("Fund VI") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP ("FPCPLSA") converted 16,407 ordinary shares to 5,469 ADSs. Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS as shown in Column 9.

F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP ("Fund VI") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP ("FPCPLSA") converted 16,407 ordinary shares to 5,469 ADSs. Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS as shown in Column 9.

SEC source: 0001209191-23-053321 · doc4.xml · derivative · entry 5

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP

Disclosed balance after: 4,101

Underlying: Ordinary Shares · 4,104 shares

Expires not disclosed

F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP ("Fund VI") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP ("FPCPLSA") converted 16,407 ordinary shares to 5,469 ADSs. Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS as shown in Column 9.

F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $65.52 to $65.70. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP ("Fund VI") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP ("FPCPLSA") converted 16,407 ordinary shares to 5,469 ADSs. Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS as shown in Column 9.

F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP ("Fund VI") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP ("FPCPLSA") converted 16,407 ordinary shares to 5,469 ADSs. Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS as shown in Column 9.

SEC source: 0001209191-23-044645 · doc4.xml · derivative · entry 3

WELCH DANIEL G · CIK 0001206199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 205,500

Underlying: Ordinary Shares · 205,500 shares

Expires 2032-01-19

F1 · kind: The reported transactions involve the Reporting Person's transfer of the vested portion of his option to trusts established for the benefit of his children. The transfer was a substitution for minority interests in a family limited partnership of equivalent value previously gifted to the trusts. The price per share is 1/3 of the closing price of the Issuer's American Depositary Shares ("ADS") on the date of transfer less the exercise price per share of the option. Each ADS consist of three of the Issuer's ordinary shares.

F1 · price: The reported transactions involve the Reporting Person's transfer of the vested portion of his option to trusts established for the benefit of his children. The transfer was a substitution for minority interests in a family limited partnership of equivalent value previously gifted to the trusts. The price per share is 1/3 of the closing price of the Issuer's American Depositary Shares ("ADS") on the date of transfer less the exercise price per share of the option. Each ADS consist of three of the Issuer's ordinary shares.

F2 · derivative.exercise_date: 1/3rd of the shares vested one year after January 5, 2022 (the "Vesting Commencement Date"); the balance of the shares vest in a series of 24 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

F4 · ownership.nature: The option is held by the Michael D. Welch 2020 Irrevocable GST Trust, dated July 1, 2020. The Reporting Person is trustee of such trust and his son and such son's descendants are the sole beneficiaries of such trust.

SEC source: 0001209191-23-044645 · doc4.xml · derivative · entry 2

WELCH DANIEL G · CIK 0001206199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 205,500

Underlying: Ordinary Shares · 205,500 shares

Expires 2032-01-19

F1 · kind: The reported transactions involve the Reporting Person's transfer of the vested portion of his option to trusts established for the benefit of his children. The transfer was a substitution for minority interests in a family limited partnership of equivalent value previously gifted to the trusts. The price per share is 1/3 of the closing price of the Issuer's American Depositary Shares ("ADS") on the date of transfer less the exercise price per share of the option. Each ADS consist of three of the Issuer's ordinary shares.

F1 · price: The reported transactions involve the Reporting Person's transfer of the vested portion of his option to trusts established for the benefit of his children. The transfer was a substitution for minority interests in a family limited partnership of equivalent value previously gifted to the trusts. The price per share is 1/3 of the closing price of the Issuer's American Depositary Shares ("ADS") on the date of transfer less the exercise price per share of the option. Each ADS consist of three of the Issuer's ordinary shares.

F2 · derivative.exercise_date: 1/3rd of the shares vested one year after January 5, 2022 (the "Vesting Commencement Date"); the balance of the shares vest in a series of 24 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

F3 · ownership.nature: The option is held by the Andrew J. Welch 2020 Irrevocable GST Trust, dated July 1, 2020. The Reporting Person is trustee of such trust and his son is the sole beneficiary of such trust.

SEC source: 0001209191-23-044645 · doc4.xml · derivative · entry 1

WELCH DANIEL G · CIK 0001206199 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 768,122

Underlying: Ordinary Shares · 411,000 shares

Expires 2032-01-19

F1 · kind: The reported transactions involve the Reporting Person's transfer of the vested portion of his option to trusts established for the benefit of his children. The transfer was a substitution for minority interests in a family limited partnership of equivalent value previously gifted to the trusts. The price per share is 1/3 of the closing price of the Issuer's American Depositary Shares ("ADS") on the date of transfer less the exercise price per share of the option. Each ADS consist of three of the Issuer's ordinary shares.

F1 · price: The reported transactions involve the Reporting Person's transfer of the vested portion of his option to trusts established for the benefit of his children. The transfer was a substitution for minority interests in a family limited partnership of equivalent value previously gifted to the trusts. The price per share is 1/3 of the closing price of the Issuer's American Depositary Shares ("ADS") on the date of transfer less the exercise price per share of the option. Each ADS consist of three of the Issuer's ordinary shares.

F2 · derivative.exercise_date: 1/3rd of the shares vested one year after January 5, 2022 (the "Vesting Commencement Date"); the balance of the shares vest in a series of 24 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

SEC source: 0001209191-23-044640 · doc4.xml · derivative · entry 1

LOVE TED W · CIK 0001188919 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Ordinary Shares · 75,000 shares

Expires 2033-08-02

F1 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").

F2 · derivative.exercise_date: The shares vest in equal monthly installments over a three-year period such that the option is fully vested on the third anniversary of August 3, 2023.

F3 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

SEC source: 0001193805-23-000724 · e618629_4-stinc.xml · derivative · entry 9

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See explanation of responses

BVF I GP LLC · CIK 0001803805 · See explanation of responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See explanation of responses

BVF II GP LLC · CIK 0001803806 · See explanation of responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See explanation of responses

BVF Partners OS Ltd. · CIK 0001660684 · See explanation of responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 462,605

Underlying: Ordinary Shares · 462,605 shares

Expires not disclosed

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · derivative.exercise_price: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · derivative.exercise_price: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F2 · kind: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · kind: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F8 · shares: Represents Non-Voting Ordinary Shares of the Issuer. Each Non-Voting Ordinary Share is convertible into one Ordinary Share, subject to the Beneficial Ownership Limitation.

F2 · price: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · price: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F2 · derivative.exercise_date: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · derivative.exercise_date: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F2 · derivative.expiration_date: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · derivative.expiration_date: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F8 · balance_after: Represents Non-Voting Ordinary Shares of the Issuer. Each Non-Voting Ordinary Share is convertible into one Ordinary Share, subject to the Beneficial Ownership Limitation.

F6 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0001193805-23-000724 · e618629_4-stinc.xml · derivative · entry 8

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See explanation of responses

BVF I GP LLC · CIK 0001803805 · See explanation of responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See explanation of responses

BVF II GP LLC · CIK 0001803806 · See explanation of responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See explanation of responses

BVF Partners OS Ltd. · CIK 0001660684 · See explanation of responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,929,660

Underlying: Ordinary Shares · 2,929,660 shares

Expires not disclosed

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · derivative.exercise_price: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · derivative.exercise_price: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F2 · kind: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · kind: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F8 · shares: Represents Non-Voting Ordinary Shares of the Issuer. Each Non-Voting Ordinary Share is convertible into one Ordinary Share, subject to the Beneficial Ownership Limitation.

F2 · price: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · price: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F2 · derivative.exercise_date: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · derivative.exercise_date: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F2 · derivative.expiration_date: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · derivative.expiration_date: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F8 · balance_after: Represents Non-Voting Ordinary Shares of the Issuer. Each Non-Voting Ordinary Share is convertible into one Ordinary Share, subject to the Beneficial Ownership Limitation.

F5 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0001193805-23-000724 · e618629_4-stinc.xml · derivative · entry 7

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See explanation of responses

BVF I GP LLC · CIK 0001803805 · See explanation of responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See explanation of responses

BVF II GP LLC · CIK 0001803806 · See explanation of responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See explanation of responses

BVF Partners OS Ltd. · CIK 0001660684 · See explanation of responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,018,253

Underlying: Ordinary Shares · 4,018,253 shares

Expires not disclosed

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · derivative.exercise_price: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · derivative.exercise_price: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F2 · kind: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · kind: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F8 · shares: Represents Non-Voting Ordinary Shares of the Issuer. Each Non-Voting Ordinary Share is convertible into one Ordinary Share, subject to the Beneficial Ownership Limitation.

F2 · price: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · price: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F2 · derivative.exercise_date: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · derivative.exercise_date: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F2 · derivative.expiration_date: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · derivative.expiration_date: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F8 · balance_after: Represents Non-Voting Ordinary Shares of the Issuer. Each Non-Voting Ordinary Share is convertible into one Ordinary Share, subject to the Beneficial Ownership Limitation.

F4 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0001193805-23-000724 · e618629_4-stinc.xml · nonDerivative · entry 3

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See explanation of responses

BVF I GP LLC · CIK 0001803805 · See explanation of responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See explanation of responses

BVF II GP LLC · CIK 0001803806 · See explanation of responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See explanation of responses

BVF Partners OS Ltd. · CIK 0001660684 · See explanation of responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · kind: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · kind: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F2 · price: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · price: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F6 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0001193805-23-000724 · e618629_4-stinc.xml · nonDerivative · entry 2

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See explanation of responses

BVF I GP LLC · CIK 0001803805 · See explanation of responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See explanation of responses

BVF II GP LLC · CIK 0001803806 · See explanation of responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See explanation of responses

BVF Partners OS Ltd. · CIK 0001660684 · See explanation of responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · kind: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · kind: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F2 · price: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · price: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F5 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0001193805-23-000724 · e618629_4-stinc.xml · nonDerivative · entry 1

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See explanation of responses

BVF I GP LLC · CIK 0001803805 · See explanation of responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See explanation of responses

BVF II GP LLC · CIK 0001803806 · See explanation of responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See explanation of responses

BVF Partners OS Ltd. · CIK 0001660684 · See explanation of responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · kind: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · kind: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F2 · price: On May 10, 2023, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 7,410,518 Ordinary Shares of the Issuer for a total of 7,410,518 newly designated Non-Voting Ordinary Shares of the Issuer (the "Non-Voting Ordinary Shares"). Pursuant to the Exchange Agreement, BVF exchanged 4,018,253 Ordinary Shares for 4,018,253 Non-Voting Ordinary Shares, BVF2 exchanged 2,929,660 Ordinary Shares for 2,929,660 Non-Voting Ordinary Shares and Trading Fund OS exchanged 462,605 Ordinary Shares for 462,605 Non-Voting Ordinary Shares.

F3 · price: Each holder of Non-Voting Ordinary Shares has the right to convert each Non-Voting Ordinary Share held by such holder into one Ordinary Share at such holder's election; provided, however, that such Non-Voting Ordinary Shares may only be converted into Ordinary Shares during such time or times such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), when aggregated with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act, in excess of 9.99% of the Ordinary Shares (the "Beneficial Ownership Limitation"). The Non-Voting Ordinary Shares have no expiration date.

F4 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 18

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned

Disclosed balance after: 0

Underlying: Ordinary Shares · 214,663 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 17

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned

Disclosed balance after: 0

Underlying: Ordinary Shares · 414,621 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 16

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned

Disclosed balance after: 0

Underlying: Ordinary Shares · 568,098 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 15

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned

Disclosed balance after: 0

Underlying: Ordinary Shares · 3,572,022 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 14

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP

Disclosed balance after: 0

Underlying: Ordinary Shares · 6,947 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 13

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP

Disclosed balance after: 0

Underlying: Ordinary Shares · 7,411 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 12

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP

Disclosed balance after: 0

Underlying: Ordinary Shares · 10,154 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 11

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP

Disclosed balance after: 0

Underlying: Ordinary Shares · 57,523 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 10

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP

Disclosed balance after: 0

Underlying: Ordinary Shares · 965,115 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

SEC source: 0000315066-23-002162 · primary_doc.xml · nonDerivative · entry 9

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned

Disclosed balance after: 4,769,404

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

SEC source: 0000315066-23-002162 · primary_doc.xml · nonDerivative · entry 8

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned

Disclosed balance after: 4,554,741

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

SEC source: 0000315066-23-002162 · primary_doc.xml · nonDerivative · entry 7

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned

Disclosed balance after: 4,140,120

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

SEC source: 0000315066-23-002162 · primary_doc.xml · nonDerivative · entry 6

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned

Disclosed balance after: 3,572,022

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

SEC source: 0000315066-23-002162 · primary_doc.xml · nonDerivative · entry 5

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP

Disclosed balance after: 82,035

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.